Ubs Asset Management Americas Inc Biogen Inc. Transaction History

Ubs Asset Management Americas Inc

$345 Billion
Q2 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Biogen Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 1,133,786 shares of BIIB stock, worth $221 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

1,133,786

Previous 972,143 16.63%

Holding current value

$221 Million

Previous $210 Million 25.38%

% of portfolio

0.08%

Previous 0.08%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$190.52 - $236.72 $30.8 Million - $38.3 Million	161,643 Added 16.63%	1,133,786 $263 Million
Q1 2024 May 15, 2024	SELL	$212.02 - $267.71 $9 Million - $11.4 Million	-42,440 Reduced 4.18%	972,143 $210 Million
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $11.3 Million - $13.6 Million	-50,935 Reduced 4.78%	1,014,583 $263 Million
Q3 2023 Nov 13, 2023	SELL	$253.3 - $285.89 $12.4 Million - $14 Million	-49,084 Reduced 4.4%	1,065,518 $274 Million
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $5.24 Million - $5.97 Million	20,411 Added 1.87%	1,114,602 $310 Million
Q4 2022 Feb 14, 2023	SELL	$252.44 - $306.72 $5.62 Million - $6.83 Million	-22,265 Reduced 1.99%	1,094,191 $303 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $7.94 Million - $11 Million	-40,807 Reduced 3.53%	1,116,456 $298 Million
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $1.13 Million - $1.35 Million	-6,049 Reduced 0.52%	1,157,263 $236 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $777,017 - $979,001	4,010 Added 0.35%	1,163,312 $245 Million
Q4 2021 Feb 14, 2022	SELL	$223.92 - $287.77 $19.2 Million - $24.7 Million	-85,684 Reduced 6.88%	1,159,302 $278 Million
Q3 2021 Nov 15, 2021	BUY	$282.99 - $369.05 $30.1 Million - $39.3 Million	106,513 Added 9.36%	1,244,986 $352 Million
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $5.52 Million - $8.84 Million	-21,311 Reduced 1.84%	1,138,473 $394 Million
Q1 2021 May 14, 2021	SELL	$242.95 - $284.63 $7.44 Million - $8.71 Million	-30,613 Reduced 2.57%	1,159,784 $324 Million
Q4 2020 Mar 01, 2021	SELL	$236.26 - $355.63 $32.9 Million - $49.5 Million	-139,251 Reduced 10.47%	1,190,397 $291 Million
Q3 2020 Nov 13, 2020	BUY	$264.77 - $305.71 $5.53 Million - $6.38 Million	20,877 Added 1.6%	1,329,648 $377 Million
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $55.4 Million - $73.4 Million	214,313 Added 19.58%	1,308,771 $350 Million
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $3.47 Million - $4.4 Million	-12,893 Reduced 1.16%	1,094,458 $346 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $11.4 Million - $15.8 Million	-51,798 Reduced 4.47%	1,107,351 $329 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $48.1 Million - $54 Million	-221,230 Reduced 16.03%	1,159,149 $270 Million
Q2 2019 Aug 15, 2019	BUY	$219.29 - $241.72 $18.4 Million - $20.3 Million	84,065 Added 6.48%	1,380,379 $0
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $33.1 Million - $51.7 Million	152,648 Added 13.35%	1,296,314 $0
Q4 2018 Feb 13, 2019	SELL	$278.5 - $352.75 $86.1 Million - $109 Million	-309,228 Reduced 21.28%	1,143,666 $344 Million
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $103 Million - $135 Million	351,238 Added 31.88%	1,452,894 $0
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $25.9 Million - $30.8 Million	100,390 Added 10.03%	1,101,656 $0
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $43.8 Million - $62 Million	168,497 Added 20.23%	1,001,266 $0
Q4 2017 Feb 09, 2018	BUY	$307.64 - $344.58 $12.6 Million - $14.1 Million	40,922 Added 5.17%	832,769 $0
Q3 2017 Nov 13, 2017	BUY	$281.15 - $329.69 $223 Million - $261 Million	791,847	791,847 $0

Others Institutions Holding BIIB

# of Institutions

1,050

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $28B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Biogen Inc. Transaction History